Although hybridoma technology remains one of the most common techniques for antibody production, the generation and screening of hybridomas can be time-con...
The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the ...
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...
In the feasibility study, scientists at the Milan site will focus on identifying proof of concept and viability for developing a prototype for an exosome-b...
Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ready-to...
AAVs make ideal gene therapy vectors due to their small size, genetic simplicity, and low immunogenicity. However, several limitations are hindering the wi...
More recently, the CRISPR system has been used to edit human induced pluripotent stem cells (iPSCs), which are known to exhibit phenotypes closer to human ...
Oligonucleotide therapeutics have unlocked new treatment possibilities for rare and fatal diseases often associated with undruggable proteins.1 Here, ...
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
Dermatology industry veteran Thibaud Portal, PhD appointed as CEO Granular Therapeutics, (Granular) a private biotech company specialising in p...
Patients with inflammatory diseases being treated with therapeutic monoclonal antibodies (mAbs) such as Infliximab may experience a significant increase in...
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...
© 2025 Biopharma Boardroom. All Rights Reserved.
